Citigroup’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.37M | Sell |
18,000
-12,000
| -40% | -$1.59M | ﹤0.01% | 2560 |
|
|
2025
Q4 | $4.25M | Buy |
+30,000
| New | +$4.35M | ﹤0.01% | 2138 |
|
|
2025
Q2 | – | Sell |
-57,000
| Closed | -$6.3M | – | 5820 |
|
|
2025
Q1 | $6.3M | Buy |
57,000
+30,000
| +111% | +$3.8M | ﹤0.01% | 1699 |
|
|
2024
Q4 | $3.69M | Sell |
27,000
-18,800
| -41% | -$2.33M | ﹤0.01% | 2259 |
|
|
2024
Q3 | $5.28M | Buy |
+45,800
| New | +$6.28M | ﹤0.01% | 1803 |
|
|
2024
Q2 | – | Sell |
-30,000
| Closed | -$4.14M | – | 5714 |
|
|
2024
Q1 | $4.14M | Hold |
30,000
| – | – | ﹤0.01% | 1849 |
|
|
2023
Q4 | $3.95M | Buy |
+30,000
| New | +$3.45M | ﹤0.01% | 1748 |
|
|
2023
Q3 | – | Sell |
-60,000
| Closed | -$5.66M | – | 5747 |
|
|
2023
Q2 | $5.66M | Buy |
60,000
+30,000
| +100% | +$2.93M | ﹤0.01% | 1423 |
|
|
2023
Q1 | $3.04M | Buy |
+30,000
| New | +$3.12M | ﹤0.01% | 1755 |
|
|
2022
Q4 | – | Sell |
-19,000
| Closed | -$2.02M | – | 5893 |
|
|
2022
Q3 | $2.02M | Buy |
19,000
+17,700
| +1,362% | +$1.8M | ﹤0.01% | 2129 |
|
|
2022
Q2 | $127K | Buy |
+1,300
| New | +$120K | ﹤0.01% | 4091 |
|
|
2021
Q1 | – | Sell |
-11,600
| Closed | -$1.11M | – | 7007 |
|
|
2020
Q4 | $1.11M | Buy |
11,600
+5,600
| +93% | +$541K | ﹤0.01% | 3435 |
|
|
2020
Q3 | $577K | Sell |
6,000
-4,200
| -41% | -$486K | ﹤0.01% | 3734 |
|
|
2020
Q2 | $1.24M | Sell |
10,200
-5,800
| -36% | -$641K | ﹤0.01% | 3322 |
|
|
2020
Q1 | $1.39M | Sell |
16,000
-7,400
| -32% | -$724K | ﹤0.01% | 2841 |
|
|
2019
Q4 | $2.52M | Sell |
23,400
-6,200
| -21% | -$649K | ﹤0.01% | 2749 |
|
|
2019
Q3 | $2.67M | Buy |
29,600
+9,400
| +47% | +$878K | ﹤0.01% | 2548 |
|
|
2019
Q2 | $1.71M | Sell |
20,200
-4,000
| -17% | -$328K | ﹤0.01% | 3045 |
|
|
2019
Q1 | $2.13M | Buy |
24,200
+7,400
| +44% | +$619K | ﹤0.01% | 2582 |
|
|
2018
Q4 | $1.2M | Buy |
16,800
+14,800
| +740% | +$1.42M | ﹤0.01% | 3209 |
|
|
2018
Q3 | $246K | Sell |
2,000
-3,100
| -61% | -$352K | ﹤0.01% | 5034 |
|
|
2018
Q2 | $501K | Buy |
5,100
+3,200
| +168% | +$286K | ﹤0.01% | 4098 |
|
|
2018
Q1 | $158K | Hold |
1,900
| – | – | ﹤0.01% | 5194 |
|
|
2017
Q4 | $147K | Sell |
1,900
-1,500
| -44% | -$102K | ﹤0.01% | 5308 |
|
|
2017
Q3 | $208K | Sell |
3,400
-43,300
| -93% | -$2.28M | ﹤0.01% | 4958 |
|
|
2017
Q2 | $2.15M | Buy |
46,700
+45,600
| +4,145% | +$2.21M | ﹤0.01% | 2513 |
|
|
2017
Q1 | $48K | Buy |
1,100
+200
| +22% | +$8.57K | ﹤0.01% | 5729 |
|
|
2016
Q4 | $35K | Sell |
900
-128,200
| -99% | -$5.8M | ﹤0.01% | 6302 |
|
|
2016
Q3 | $6.54M | Buy |
129,100
+6,600
| +5% | +$329K | 0.01% | 1427 |
|
|
2016
Q2 | $5.57M | Buy |
122,500
+122,300
| +61,150% | +$5.63M | 0.01% | 1486 |
|
|
2016
Q1 | $8K | Sell |
200
-3,800
| -95% | -$151K | ﹤0.01% | 6865 |
|
|
2015
Q4 | $226K | Buy |
4,000
+3,900
| +3,900% | +$198K | ﹤0.01% | 4632 |
|
|
2015
Q3 | $4K | Buy |
+100
| New | +$4.83K | ﹤0.01% | 6826 |
|
Other funds holding NBIX
VPM
VCM
Citigroup's NBIX Position: Q1 2026 in Review
Citigroup increased its Neurocrine Biosciences (NBIX) stake by 8.9% in Q1 2026, buying an estimated $1.22M and bringing the position to 112,442 shares worth $14.8M. The position accounts for 0.01% of the portfolio, ranked #1241.
Citigroup first reported a position in NBIX in Q2 2013 and has held it in 52 quarters since. The position peaked at $51.6M in Q1 2025. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.
- Citigroup held 112,442 shares of Neurocrine Biosciences worth $14.8M as of Q1 2026.
- Citigroup bought 9,169 Neurocrine Biosciences shares in Q1 2026, an estimated $1.22M.
- Neurocrine Biosciences made up 0.01% of Citigroup's portfolio in Q1 2026, its #1241 holding.
- Citigroup first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 52 quarters since.
- Citigroup's Neurocrine Biosciences position peaked at $51.6M in Q1 2025.
- 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.
Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.